AVI Ends June With $20M Cash

Xconomy Seattle — 

AVI Biopharma, the Bothell, WA-based developer of RNA-based therapies, said today in its quarterly financial report that it had $20.2 million in cash and investments at the end of June. The company (NASDAQ: AVII) expects to spend $10 to $12 million on operations this year, and said it anticipates it will receive more funding this year from governments and other sources.